EVISTA 60mg - DAIICHI SANKYO
Evista is Daiichi Sankyo's brand name for raloxifen hydrochloride, a second-generation Selective Estrogen Receptor Modulator (SERM) in the benzothiophene family. On September 13, 2007, the U. S. Food and Drug Administration approved Evista for reduction in the risk of invasive breast cancer in postmenopausal women with and without osteoporosis. It has also been approved as a potent stand-alone osteoporosis treatment.
Essentially Evista is a non-steroidal, anti-estrogenic drug that possesses both estrogen agonist and antagonist properties. This means that how it acts estrogen promoting with regard to bones, or anti-estrogenic towards uterine and breast tissue depends on the absorption site, i.e. which receptors within the body are absorbing it.
Evista, and raloxifene hydrochloride in general, is most often found in the form of 60 mg tablets. One tablet should be taken daily with or without food. If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next dose, skip the missed dosage and take only the next regularly scheduled dose. Do not take two doses at the same time.
For bodybuilding/athletic purposes, within the male body, Evista primarily acts as an anti-estrogen. Aromatization is the process by which excess testosterone is readily converted to excess estrogen, which when absorbed by various estrogen receptors throughout the body can incite numerous negative side effects the most hazardous of which is probably gynecomastia (gyno) the development of female breast tissue in men, a condition caused by an imbalance in the testosterone to estrogen ratio.
Evista's actions are very similar to those of more popular anti-estrogens frequently used within the anabolic steroid community such as Tamoxifen (Nolvadex) and Clomiphene Citrate (Clomid), two drugs that effectively block estrogens absorption because they are preferred by the estrogen receptors. Anabolic steroid using bodybuilders and athletes take these drugs to prevent said estrogen absorption, causing it to instead continue circulating ineffectively throughout the bloodstream. Estrogens lack of absorption significantly reduces estrogenic side effects, as well as prohibits gynos development by starving existing gyno growth of the nourishing estrogen necessary to sustain and/or increase it. Without access to estrogen gyno shrinks, and in most cases completely dissolves resulting in full resolution. In a small percentage of cases the growth persists, but shrinks substantially and remains susceptible to redevelopment in subsequent steroid cycles if not properly protected against.
There are a host of Daiichi Sankyo cited major possible side effects (of course for women only as per this drugs prescription population), but most are manufacturer safeguards like blood clots, stroke and death from either complication. For the male steroid user, Evista possesses potential for the same major side effects but of course the relatively minor ones are far more common such as irritability, mood swings, joint stiffness or pain, temporarily negative lipid panel & hepatic results, and possible libido hindrance.
Evista is typically administered after anabolic steroid cycles including Stanozolol, Anavar, Primobolan, testosterone (propionate, enanthate, and cypionate), Trenbolone, Oral Turinabol, Deca-Durabolin, and Halotestin. This is called Post-Cycle Therapy (PCT), a process that bridges the time between cycle discontinuation and the restoration of HPTA.
Only going with PharmaComStore for ancillaries in the future and probably gear too